Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago.

Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG;

Read the full 444 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE